Patent Office Issues EMED Notice of Allowance for a New Patent
EMED Technologies today announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance on September 28, 2017 for the newest patent in the Company's needle securement family — covering multiple aspects of EMED's proprietary safety wing designs.
The new patent further complements EMED's needle securement intellectual property portfolio and is expected to be formally issued in the months ahead.
"We are proud of our continued innovation in clinical protocols and remain committed to providing best-in-class medical devices to the patients and clinicians who rely on them every day."
Paul LambertChief Executive Officer, EMED Technologies
The patent aligns with EMED's pioneering work in the design of home infusion devices for SCIg (Subcutaneous Immunoglobulin) used in Primary Immunodeficiency therapy and other conditions requiring regular infusion.
For more information about EMED's full portfolio of infusion solutions and patents, visit emedtc.com and emedtc.com/patents.
About EMED
EMED Technologies is an industry leader in the design, manufacture, and distribution of cutting-edge medical devices. For two decades, EMED Technologies has worked with clinicians, inventors, and medical companies to develop innovative medical products. Today, we are proud that both patients and clinicians can benefit from the fruits of our labor because we offer a wide variety of products and services that improve therapies and enhance clinical benefits. With our dynamic team of professionals, EMED continues to work with clinicians to understand their requirements and improve upon available technologies. In addition to novel technology, EMED is proud to offer licensing agreements for patented and proprietary technologies.
Media contact
For media inquiries, please contact info@emedtc.com.
Original release
The full press release is available on PR Newswire.